Ultragenyx Pharmaceutical Inc (MEX:RARE)
MXN 751.98 0 (0%) Market Cap: 65.87 Bil Enterprise Value: 59.05 Bil PE Ratio: 0 PB Ratio: 23.46 GF Score: 70/100

Ultragenyx Pharmaceutical Inc SETRUSUMAB Phase 2 Data Conference Call Transcript

Jun 05, 2023 / 09:00PM GMT
Release Date Price: MXN887.76
Operator

Good afternoon, and welcome to the UX143 Phase II Data Conference Call. (Operator Instructions)

It is now my pleasure to turn the call over to Joshua Higa, Vice President and Head of Investor Relations.

Joshua Higa;Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - Director of IR & Corporate Communications;Ultragenyx Pharmaceutical Inc

Thank you. Earlier today, we issued a press release and updated slides in our corporate deck that outlined the positive results from the Phase II Orbit study in osteogenesis imperfecta, both of which you can find on our website at ultragenyx.com.

Joining me today are Emil Kakkis, Chief Executive Officer and President; and Eric Crombez, Chief Medical Officer.

I'd like to remind everyone that during today's call, we'll be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. Please refer to the risk factors discussed in our latest SEC filings. I'll now turn the call over to Emil.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot